Bridgefront Capital’s Akero Therapeutics AKRO Stock Holding History

Bridgefront Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,305	Closed	-$299K	–	505
2025 Q3	$299K	Buy	+6,305	New	+$305K	0.09%	391
2025 Q2	–	Sell	-10,736	Closed	-$435K	–	588
2025 Q1	$435K	Buy	+10,736	New	+$455K	0.13%	293
2021 Q3	–	Sell	-12,099	Closed	-$300K	–	313
2021 Q2	$300K	Buy	+12,099	New	+$340K	0.11%	341

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridgefront Capital's AKRO Position: Q4 2025 in Review

Bridgefront Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,305 shares — an estimated $299K sold.

Bridgefront Capital first reported a position in AKRO in Q2 2021 and held it in 3 quarters. The position peaked at $435K in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Bridgefront Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 6,305 Akero Therapeutics shares in Q4 2025, an estimated $299K.
Bridgefront Capital first reported a position in Akero Therapeutics in Q2 2021 and held it in 3 quarters.
Bridgefront Capital's Akero Therapeutics position peaked at $435K in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.